Nuvectis Pharma Inc (NVCT) is next scheduled to report earnings on Aug 4, 2026. The consensus analyst EPS estimate for the upcoming quarter is $-0.25.
Heading into this report, the model's fair value estimate sits 12.1% above the current price (model fair value differential below current price). Descriptive context only — not a forecast of the earnings result.
Equity Rank computed model fair value for NVCT from 1 independent valuation methods with sufficient data. 0 place fair value above the current price of $14.14, and 1 place it below. The model-blended estimate lands at $12.43 — a model fair value differential of 12.1% below the current price under these model assumptions. The larger group places fair value below the current price.
Equity Rank's fundamental strength composite scores NVCT at 26.8/100 (D-, Weak), blending profitability, balance-sheet, and cash-flow quality.
Nuvectis Pharma Inc (NVCT) is analyzed on Equity Rank using the S·A·V·E framework: Sentiment, Analyst consensus, Valuation (DCF, Graham, multiples), and Earnings quality. The consensus fair value is a blend of multiple models designed to surface potential mispricings versus current market price.
Equity Rank provides institutional-depth valuation research on 3,000+ US equities. Data is refreshed daily and combines quantitative models with AI-driven qualitative analysis.
Intrinsic Value Calculator · DCF Calculator · Margin of Safety Calculator